Qurient Co. Ltd - Asset Resilience Ratio

Latest as of March 2026: 62.41%

Qurient Co. Ltd (115180) has an Asset Resilience Ratio of 62.41% as of March 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing.

Liquid Assets

₩34.14 Billion
≈ $23.14 Million USD Cash + Short-term Investments

Total Assets

₩54.70 Billion
≈ $37.07 Million USD All company assets

Resilience Assessment

Very High
Financial Resilience Level

Asset Resilience Ratio Trend (2016–2025)

This chart shows how Qurient Co. Ltd's Asset Resilience Ratio has changed over time. Check strategic asset allocation of Qurient Co. Ltd to assess the company's strategic physical and investment asset allocation.

Liquid Assets Composition Over Time

This chart breaks down Qurient Co. Ltd's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see Qurient Co. Ltd (115180) market capitalisation.

Current Liquid Assets Breakdown

Component Amount % of Total Assets
Cash & Equivalents ₩0.00 0%
Short-term Investments ₩34.14 Billion 62.41%
Total Liquid Assets ₩34.14 Billion 62.41%

Asset Resilience Insights

  • Very High Liquidity: Qurient Co. Ltd maintains exceptional liquid asset reserves at 62.41% of total assets.
  • This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
  • The company has significant short-term investments, indicating active treasury management.

Qurient Co. Ltd Industry Peers by Asset Resilience Ratio

Compare Qurient Co. Ltd's asset resilience ratio with other companies in the same industry.

Company Industry Asset Resilience Ratio
Tubize-Fin
BR:TUB
Biotechnology 0.05%
Verona Pharma plc
F:I9SA
Biotechnology 0.00%
Xiamen Amoytop Biotech Co Ltd
SHG:688278
Biotechnology 4.69%
Syndax Pharmaceuticals Inc
NASDAQ:SNDX
Biotechnology 46.79%
Neuren Pharmaceuticals Ltd
AU:NEU
Biotechnology 90.43%
Vor Biopharma Inc
NASDAQ:VOR
Biotechnology 63.47%
Chengdu Kanghua Biological Products
SHE:300841
Biotechnology 1.19%
Jiangsu Aidea Pharmaceutical Co Ltd
SHG:688488
Biotechnology 4.35%

Annual Asset Resilience Ratio for Qurient Co. Ltd (2016–2025)

The table below shows the annual Asset Resilience Ratio data for Qurient Co. Ltd.

Year Asset Resilience Ratio (%) Liquid Assets Total Assets Change
2025-12-31 46.80% ₩29.02 Billion
≈ $19.66 Million
₩61.99 Billion
≈ $42.01 Million
-23.82pp
2024-12-31 70.62% ₩46.31 Billion
≈ $31.38 Million
₩65.57 Billion
≈ $44.44 Million
-7.24pp
2023-12-31 77.86% ₩40.88 Billion
≈ $27.70 Million
₩52.50 Billion
≈ $35.58 Million
+9.74pp
2022-12-31 68.12% ₩26.17 Billion
≈ $17.73 Million
₩38.41 Billion
≈ $26.03 Million
+10.09pp
2021-12-31 58.03% ₩33.44 Billion
≈ $22.66 Million
₩57.62 Billion
≈ $39.05 Million
-22.76pp
2018-12-31 80.80% ₩34.90 Billion
≈ $23.65 Million
₩43.20 Billion
≈ $29.27 Million
+17.69pp
2017-12-31 63.10% ₩9.89 Billion
≈ $6.70 Million
₩15.68 Billion
≈ $10.62 Million
+55.48pp
2016-12-31 7.62% ₩2.00 Billion
≈ $1.36 Million
₩26.24 Billion
≈ $17.78 Million
--
pp = percentage points

About Qurient Co. Ltd

KQ:115180 Korea Biotechnology
Market Cap
$434.60 Million
₩641.30 Billion KRW
Market Cap Rank
#12827 Global
#343 in Korea
Share Price
₩17210.00
Change (1 day)
+3.30%
52-Week Range
₩10000.00 - ₩50900.00
All Time High
₩50900.00
About

Qurient Co., Ltd., a biotech company, engages in the research and development of drugs to address unmet medical needs in Korea and internationally. The company's pipeline products include Q301, a topical 5LO inhibitor, which is in Phase II clinical trial for the treatment of atopic dermatitis; and Telacebec (Q203), Cyt bc1 Inhibitor, that is in Phase II to treat Mycobacterial Infections, such as … Read more